Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000788603 | SCV000927772 | likely pathogenic | not provided | 2018-07-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003243296 | SCV003964631 | uncertain significance | Inborn genetic diseases | 2023-04-14 | criteria provided, single submitter | clinical testing | The c.6752_6754delTGG (p.V2251del) alteration is located in exon 15 (coding exon 15) of the PKD1 gene. This alteration consists of an in-frame deletion of 3 nucleotides between nucleotide positions c.6752 and c.6754, resulting in the deletion of <NA> residues. This alteration is predicted to be deleterious by in silico analysis (Choi, 2012). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003396369 | SCV004105098 | uncertain significance | PKD1-related disorder | 2023-08-09 | criteria provided, single submitter | clinical testing | The PKD1 c.6752_6754delTGG variant is predicted to result in an in-frame deletion (p.Val2251del). This variant was reported in three individuals with polycystic kidney disease 1 (Table S4, Carrera et al. 2016. PubMed ID: 27499327; Table S6, Kim et al. 2019. PubMed ID: 31740684; Table 1, Li et al. 2022. PubMed ID: 34739738). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Genetic Services Laboratory, |
RCV000788603 | SCV003839854 | likely pathogenic | not provided | 2022-02-28 | no assertion criteria provided | clinical testing | DNA sequence analysis of the PKD1 gene demonstrated a three base pair deletion in exon 15, c.6752_6754del. This in-frame deletion is predicted to result in the deletion of a single amino acid residue, p.Val2251del. This deletion has been previously described in individuals with polycystic kidney disease (PMID: 31740684, 27499327). The c.6752_6754del sequence change has not been described in the population databases such as ExAC and gnomAD. This sequence change is the likely cause of this individual's phenotype, however functional studies have not been performed to prove this conclusively. |
Zotz- |
RCV003333756 | SCV004041624 | uncertain significance | Polycystic kidney disease, adult type | 2023-10-09 | no assertion criteria provided | clinical testing |